H eart failure (HF) is an increasing public health concern in the United States, currently affecting >5.7 million adults aged >20. 1 Among patients with HF, ≈50% have normal to near normal left ventricular ejection fraction (EF), 2-5 and the percentage of patients with HF with preserved EF (HFpEF) is expected to rise with the ageing population and the anticipated increase in the prevalence of obesity, hypertension, and diabetes mellitus. 6 The increasing prevalence of this disorder warrants an enhanced understanding of its effect beyond mortality, to include, psychosocial factors, such as quality of life (QOL) and depression, critically important outcomes from patients' perspectives. 7, 8 
Compared with other chronic diseases and other cardiac conditions, patients with HF are more likely to report impaired QOL, 9, 10 and this impairment has shown to directly correlate with worsening New York Heart Association (NYHA) functional class. 11 One of the factors contributing to the poor QOL is depression that has been reported to affect 1 out of every 4 individuals with HF. 12 Among patients with HF, concurrent depression has been shown to affect the perception of disease severity, with an increase in subjective symptoms of HF as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) and NYHA. 13, 14 The association of depressive symptoms with health status in HFpEF has not been described and may have different prevalence, risk factors, and implications than those with systolic dysfunction.
The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT) is a randomized controlled study examining cardiovascular outcomes in participants with HFpEF treated with spironolactone versus placebo. The present analysis aims to identify predictors of both impaired QOL and depression among participants with HFpEF and to determine the correlation between QOL and depression. We think that by identifying the features commonly associated with poor QOL and depression, we will be able to further illuminate the role these factors play in HFpEF and ultimately, identify how improving QOL and depression can affect symptom severity and potentially overall prognosis in this disorder.
Methods

Patient Population
The design for TOPCAT was described previously. 15 Briefly, TOPCAT was a multicenter, international, randomized, double blind, placebocontrolled trial of spironolactone in participants with HFpEF. TOPCAT was conducted with the approval of local institutional review boards. The countries involved in the study include the United States, Canada, Russia, Republic of Georgia, Brazil, and Argentina. Participants were enrolled from August 2006 to January 2012. The primary aim of the study was to compare the effectiveness of spironolactone when compared with placebo, in decreasing the composite incidence of cardiovascular death, hospitalization for HF, or aborted cardiac arrest. Secondary aims included the effect on QOL, nonfatal cardiovascular events, and new-onset atrial fibrillation. Subjects enrolled in the study were men and women aged ≥50 years, with a left ventricular EF of ≥45%, and either a report of hospitalization within the year before randomization with HF as a major component (hospitalization stratum), or in the absence of such hospitalization an elevated natriuretic peptide level within 60 days before randomization (natriuretic peptide stratum). Major exclusion criteria included a life expectancy of <3 years, uncontrolled hypertension, constrictive pericarditis, known infiltrative or hypertrophic cardiomyopathy, history of serious or unprovoked hyperkalemia, and an estimated glomerular filtration rate of <30 mL/min per 1.73 m 2 .
Assessment of QOL and Depression
Three questionnaires were used to assess the QOL and depression for TOPCAT participants, the KCCQ for assessing disease-specific health status, 16 the European QOL 5-Dimension Visual Analog Scale (EQ-5D VAS) 17 for assessing general health status, and the Patient Health Questionnaire (PHQ-9) 18 to assess depressive symptoms. PHQ-9 was only given to subjects from the United States and Canada because it was not validated for use in the languages of other countries. All 3 assessment tools were used at the baseline visit and protocol-specific follow-up visits, thereafter, through the end of study. KCCQ is a 23-item self-administered questionnaire developed to evaluate the health status of patients with HF, their symptoms, function, and health-related QOL. Distinct scales quantify physical limitation, symptoms (frequency, severity, and change over time), QOL, social interference, and self-efficacy. Each response is given an ordinal value, and scale scores are transformed into a 0 to 100 range, with higher scores indicating better health status. 16 EQ-5D VAS is a vertical scale from 0 to 100, with 0 representing the worst possible health and 100 representing the best possible health. 17 PHQ-9 is a 9-item depression questionnaire with scores categorized as 0 to 4 (no/ minimal depressive symptoms), 5 to 9 (mild depressive symptoms), 10 to 14 (moderate depressive symptoms), 15 to 19 (moderate-severe depressive symptoms), and 20 to 27 (severe depressive symptoms). 18
Statistical Analysis
The total number of TOPCAT subjects was 3445. Of those, 3400 subjects (98.7%) had baseline KCCQ data and 3395 (98.5%) had baseline EQ-5D data. PHQ-9 was only completed in the United States and Canada (n=1477), and of those, 1431 (96.9%) had baseline PHQ-9 data. For the analyses of this article, we excluded the subjects with missing data. Means, SDs, and quartiles were presented for KCCQ overall summary scores and subscales (clinical summary score, symptom stability score, physical limitation score, self-efficacy score, symptom score, social limitation score, and QOL score) and for EQ-5D VAS scores. The number and percentage of participants in each of the 5 PHQ-9 categories (0-4, 5-9, 10-14, 15-19, and 20-27) were reported.
The baseline characteristics obtained were compared based on depression status (no depression [0-9] versus depression [10+]) and based on prespecified groupings (0-25, 26-50, 51-75, and 76-100) of the KCCQ overall summary score and EQ-5D VAS score. Descriptive statistics were reported as the number and percentage for categorical and ordinal variables, the mean and SD for continuous variables with a general normal distribution, and the median and interquartile range for other continuous variables. Comparisons between groups were done via t test or ANOVA for continuous variables and χ 2 tests for categorical variables.
The factors predictive of depressive symptoms and impaired QOL were determined based on multiple logistic regression analysis for dichotomous PHQ-9 (depression [10+] versus no depression [0-9]) and multiple linear regression analysis for continuous KCCQ overall summary scores and EQ-5D VAS scores. The model selection process used the backward elimination method, starting with a model including all significant variables assessed in the baseline characteristics comparisons plus the variable used to stratify randomization (hospitalization stratum versus natriuretic peptide stratum). Stratum was forced to remain in the model at all steps of the elimination process.
The correlations between total KCCQ overall summary score and PHQ-9 score, as well as, between EQ-5D VAS score and PHQ-9 score, and between KCCQ overall summary score and EQ-5D VAS score were assessed by graphical methods and Pearson correlations.
Statistical analyses were performed at the Data Coordinating Center (New England Research Institute, Watertown, MA) with SAS software, release 9.3 (SAS Institute Inc, Cary, NC). Two-tailed P values <0.05 were considered statistically significant.
Results
Quality of Life
The mean overall summary score on KCCQ was 54.8. The mean scores for physical limitation, social limitation, and QOL score were 56.1, 54.9, and 49.9, respectively, indicative of moderate limitation, and the EQ-5D VAS mean total score was 60.3 ( Table  I in the Data Supplement). Among participants who completed EQ-5D VAS (n=3395), 80% (2716) had an overall summary score within the range of 26 to 75. Among participants who completed KCCQ (n=3400), 75% (n=2541) of participants had an overall summary score within the range of 26 to 75.
QOL assessments were given to all participants, whereas PHQ-9 was only administered in North Americans with differences in characteristics detailed in In bivariate analyses comparing baseline characteristics of subjects in the 4 EQ-5D categories, the majority of participants with the most impaired QOL (EQ-5D VAS score, 0-25 points) were classified as NYHA class III or IV, whereas the majority of those with the least impaired QOL (EQ-5D VAS score, 76-100 points) were classified as NYHA class I or II. Participants from the Americas scored higher on EQ-5D compared with those from Eastern Europe. Participants with angina pectoris, coronary artery disease, asthma, diabetes mellitus, atrial fibrillation, stroke, obesity, peripheral arterial disease, implanted cardiac-defibrillator, percutaneous coronary intervention, coronary artery bypass grafting, and dyslipidemia more often scored within the lowest group (0-25 points) on EQ-5D. In addition, participants on a hypoglycemic agent and statin more often scored within the lowest group (0-25 points), whereas those on warfarin and angiotensin receptor blockers scored within the highest group (76-100; Table III in the Data Supplement). Table 2 shows the results of multivariable analyses of factors associated with KCCQ and EQ-5D VAS. The correlates of better KCCQ and better EQ-5D VAS at baseline via multiple linear regression analysis were American region (compared with Eastern Europe), older age, patients without a history of angina pectoris, asthma, use of a hypoglycemic agent, higher activity level, and lower NYHA class. Additional correlates of either better KCCQ or better EQ-5D at baseline are also presented in Table 2 .
Depression
Among the study participants (n=1431) completing the PHQ-9 depression questionnaire, 1049 (73%) had minimal to mild depression (score, 0-9), whereas 382 (27%) had moderate to severe depression (score, 10+; Table I in the Data Supplement). Many baseline characteristics were associated with depression in bivariate analyses. Study participants who were depressed were more likely to be women and younger than those without depression (average age, 67.5±10.0 years and 72.5±9.5 years, respectively). Non-Hispanic whites were less likely to be depressed. Participants with angina pectoris, coronary artery disease, diabetes mellitus, obesity, chronic obstructive pulmonary disease, and asthma were more likely to be depressed ( Table IV in the Data  Supplement) . Depressed participants were more likely to be in NYHA class III or IV HF compared with nondepressed patients. In addition, participants taking diuretics, angiotension-converting enzyme inhibitors, and hypoglycemic agents had a higher prevalence of depression, whereas participants with atrial fibrillation and on warfarin were less likely to be depressed. There was no difference in smoking status, cooking salt score, or percentage of home meals between the 2 groups. However, participants without depression reported higher activity levels (3.3 Metabolic Equivalent of Task (MET)-hours/wk versus 1.0 MET-hours/wk; Table IV in the Data Supplement). As expected, participants with higher scores on PHQ-9 were more likely to use antidepressants than those with lower scores ( 13.7% of those with scores 0-9). Correlates of depression via multiple logistic regression analysis included younger age, female sex, comorbid angina, chronic obstructive pulmonary disease, use of a hypoglycemic agent, lower activity level, higher NYHA class, and selective serotonin reuptake inhibitor use (Table 3 ).
In the unadjusted models, hospitalization stratum was a significant variable associated with lower KCCQ and EQ-5D scores (P<0.0001 for each) and higher PHQ-9 scores (P=0.0428). In the adjusted models, hospitalization stratum did not reach statistical significance for KCCQ (P=0.053) and was no longer significantly related to EQ-5D scores (P=0.956) or to PHQ-9 scores (P=0.417).
There were moderately strong correlations between high KCCQ overall summary scores and low PHQ-9 scores ( Figure  A) , high EQ-5D VAS and low PHQ-9 scores ( Figure B) , and high KCCQ and high EQ-5D VAS scores ( Figure C; P<0 .001 for each).
Discussion
To date, detailed assessments of the health-related QOL and depression status of patients with HFpEF have been rarely assessed. In one of the largest HFpEF studies ever conducted, we found that patients with HFpEF often have impaired QOL and depression based on KCCQ, EQ-5D VAS, and PHQ-9. Moreover, we were able to define patient-level characteristics associated with worse health status and more severe depressive symptoms.
Certain lifestyle factors were found to contribute to the effects of HF on QOL. A recent study conducted in Spain found that alcohol drinkers, even those characterized as heavy drinkers, reported superior health-related QOL compared with nondrinkers. 19 Another study of participants in the United States found that frequent low-quantity drinkers had the highest overall health-related QOL. 20 It is therefore interesting that all levels of alcohol use were associated with better KCCQ in the present analysis compared with no alcohol consumption (although the difference was not statistically significant for every category of drinking). However, this study was conducted with an international patient population, and the results may be attributed to cultural variations in alcohol consumption patterns. 21 Previous studies have demonstrated the use of salt restriction in improving NYHA class and peripheral edema, 22 as well as 30-day hospital readmission rates. 23 The finding that a lower cooking salt score was predictive of better KCCQ scores further supports the potential role for diet modification in participants with HF. However randomized controlled trials showing the benefits of salt and fluid restriction in HF are required. †Stratum was forced into model.
Figure.
Correlation between (A) Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score and Patient Health Questionnaire (PHQ-9) total score, (B) European QOL 5D Visual Analog Scale (EQ-5D VAS) score and PHQ-9 total score, and (C) EQ-5D VAS score and KCCQ overall summary score.
According to the Center for Disease Control, in the general population, men and women aged 40 to 59 years have higher rates of depression compared with those aged ≥60. 24 This is consistent with higher rates of depression seen in younger individuals with HF in this study. 13 Data suggest that depression and anxiety may decrease with age because of decreased emotional responsiveness, increased emotional control, and psychological immunization, or resistance to adverse life events with repeated exposure. 25, 26 Healthrelated QOL is mediated not only by symptom severity but also by perception of health. 27 The variation in depression and QOL across age may be explained by a discrepancy between functional status and the expectation of what one's functional capacity should be. It is possible that younger individuals experience more difficulty coping with a physically and emotionally limiting disorder, such as HF, whereas older individuals are more expectant of limitations associated with advanced age.
Sex is another factor that plays a role in health perception, as women in TOPCAT with HF had higher rates of depression and worse QOL compared with men as shown previously. 13, 28 Both physiological and psychosocial differences between men and women may account for these findings. Women have a lower percentage of ischemic cause of HF, higher left ventricular EF, and higher heart rate than men. 29 Furthermore, women with HF are at higher risk of psychosocial distress and have a greater need for social support. 30 These differences should be considered when treating women with this disorder, especially, because HFpEF is more common in women. 2 The American Heart Association recommends screening participants with cardiovascular disease for depression using PHQ-9. 31 A PHQ-9 score of ≥10 has been shown to have a specificity of 90%, a sensitivity of 54%, and a negative predictive value of 88% for detecting depression. 32 As expected, a PHQ-9 score of ≥10 in this study was associated with higher use of selective serotonin reuptake inhibitor (22.8% versus 13.7% for PHQ-9 scores ≤10). Impaired QOL as measured by KCCQ has been associated with poor prognosis. 33, 34 Furthermore, the study demonstrated a significant correlation between PHQ-9 and both the KCCQ and EQ-5D VAS measures of QOL. In addition, this study demonstrates a significant correlation between EQ-5D VAS and KCCQ confirming the use of both these tools in assessing health-related QOL among participants with HFpEF.
Depression has been linked to a 2-to 3-fold higher mortality rate and a 3-fold higher incidence of rehospitalization in participants with HF, independent of age, NYHA class, and baseline EF. 35, 36 In a study of participants with end-stage HF, depressed participants had a significantly higher risk of cardiovascular death compared with nondepressed participants. 37 Furthermore, a 3-year retrospective study found that annualized adjusted costs were ≈30% greater for participants with HF diagnosed with depression. 38 Management of depression has the potential to improve QOL among these participants. 39, 40 Findings of this study suggest a potential role for the screening of depression and QOL in younger participants and women, as well as participants with comorbid chronic obstructive pulmonary disease and angina pectoris. In addition, there may be a benefit to initiating treatment of depression among these participants in an effort to improve overall prognosis of HF. However, randomized controlled trials evaluating the use of treatment of depression among these patient populations are required.
Limitations
This study was limited by the fact that PHQ-9 was only given to subjects from the United States and Canada because it was not validated for use in the languages of other countries. This may affect the generalizability of the data to the international patient population. Furthermore, this study was not primarily designed with the intent of examining QOL and depression in participants with HFpEF, but it was instead a subanalysis of a large randomized controlled trial examining the effects of a spironolactone treatment for HFpEF.
Conclusions
Patients with HFpEF, especially those with higher NYHA functional class, and those who were younger, had comorbid angina pectoris, had lower activity levels, or were using hypoglycemic agents were more likely to have impaired QOL and depression based on PHQ-9, KCCQ, and EQ-5D VAS. In addition, certain lifestyle variables, such as alcohol use and cooking salt, play a role as well. This demonstrates a potential role for screening for depression and QOL among participants with HFpEF and the need for further studies examining the potential benefit of intervention to improve patient outcomes.
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